PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Thomas Eden

Evotec SE, Manfred Eigen Campus Institution, Hamburg, Germany.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

JUN 10, 2026 · JOURNAL ARTICLE

Combination therapy with a novel CD2-targeted costimulatory bispecific antibody overcomes limitations of CD3 T cell engager treatment for solid tumors.

Mabs

Preclinical proof-of-concept study in xenograft models demonstrating enhanced anti-tumor activity with a novel CD2-targeted bispecific; no clinical efficacy or safety data provided.

PreliminaryAntibody Engineering Xenograft Model Antitumor Assays Lise Pasquet

Reported

Complete tumor remission with com…8 of 9 mice

Complete tumor remission with TCE…1 of 9 mice

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support